Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2017 12:31 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Present at Two Upcoming Investor Conferences

EMERYVILLE, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., the company’s Chairman and Chief Executive Officer, is...
March 28, 2017 10:32 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Present at the 16th Annual Needham Healthcare Conference

EMERYVILLE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is...
March 01, 2017 14:43 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas to Present at the 37th Annual Cowen Health Care Conference

EMERYVILLE, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is...
January 06, 2017 09:00 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease

-- PDUFA Action Date Set for August 24, 2017 -- -- If Approved, ADS-5102 will be the First and Only Medicine Approved for the Treatment of LID in Parkinson’s Disease -- EMERYVILLE, Calif.,...
January 03, 2017 16:52 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy

EMERYVILLE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the completion of a Phase 1 clinical trial of ADS-4101, an investigational drug in...